Weekly Investment Analysts’ Ratings Updates for Regenxbio (RGNX)

Regenxbio (NASDAQ: RGNX) has recently received a number of price target changes and ratings updates:

  • 5/29/2019 – Regenxbio was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 5/11/2019 – Regenxbio was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland. “
  • 5/10/2019 – Regenxbio was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 5/10/2019 – Regenxbio was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating.
  • 5/9/2019 – Regenxbio was downgraded by analysts at TheStreet from a “c” rating to a “d+” rating.
  • 5/7/2019 – Regenxbio was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $58.00 price target on the stock. According to Zacks, “REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland. “
  • 5/2/2019 – Regenxbio was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 4/26/2019 – Regenxbio was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 4/16/2019 – Regenxbio was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.

Shares of RGNX stock traded down $2.93 during trading hours on Thursday, reaching $43.72. 718,473 shares of the stock were exchanged, compared to its average volume of 562,723. The company has a debt-to-equity ratio of 0.01, a quick ratio of 14.21 and a current ratio of 14.21. Regenxbio Inc has a 12-month low of $38.56 and a 12-month high of $85.10. The firm has a market capitalization of $1.79 billion, a price-to-earnings ratio of 18.37 and a beta of 0.37.

Regenxbio (NASDAQ:RGNX) last released its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.89) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.85) by ($0.04). Regenxbio had a negative return on equity of 9.90% and a negative net margin of 41.99%. The firm had revenue of $0.88 million for the quarter. Equities analysts forecast that Regenxbio Inc will post -3.21 EPS for the current fiscal year.

In related news, SVP Curran Simpson sold 18,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $50.00, for a total value of $900,000.00. Following the completion of the transaction, the senior vice president now directly owns 57,500 shares of the company’s stock, valued at $2,875,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Vittal Vasista sold 3,068 shares of the company’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $60.01, for a total value of $184,110.68. Following the completion of the transaction, the chief financial officer now directly owns 239,215 shares of the company’s stock, valued at $14,355,292.15. The disclosure for this sale can be found here. Insiders sold 83,068 shares of company stock valued at $4,342,481 over the last ninety days. 13.80% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in RGNX. Berman Capital Advisors LLC acquired a new stake in shares of Regenxbio in the fourth quarter valued at approximately $33,000. Mckinley Capital Management LLC Delaware boosted its holdings in shares of Regenxbio by 51.8% in the first quarter. Mckinley Capital Management LLC Delaware now owns 888 shares of the biotechnology company’s stock valued at $51,000 after acquiring an additional 303 shares during the period. Financial Gravity Wealth Inc. acquired a new stake in shares of Regenxbio in the first quarter valued at approximately $55,000. PNC Financial Services Group Inc. boosted its holdings in shares of Regenxbio by 568.5% in the first quarter. PNC Financial Services Group Inc. now owns 1,190 shares of the biotechnology company’s stock valued at $68,000 after acquiring an additional 1,012 shares during the period. Finally, NumerixS Investment Technologies Inc acquired a new stake in shares of Regenxbio in the fourth quarter valued at approximately $50,000. 81.67% of the stock is owned by hedge funds and other institutional investors.

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Featured Story: Growth Stocks

Receive News & Ratings for Regenxbio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio Inc and related companies with MarketBeat.com's FREE daily email newsletter.